Co-DiagnosticsCODX
CODX
About: Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Employees: 132
0
Funds holding %
of 7,431 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
2.41% less ownership
Funds ownership: 17.41% [Q1] → 15.0% (-2.41%) [Q2]
13% less funds holding
Funds holding: 38 [Q1] → 33 (-5) [Q2]
22% less capital invested
Capital invested by funds: $1.81M [Q1] → $1.41M (-$395K) [Q2]
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
3,026%
upside
Avg. target
$10
3,026%
upside
High target
$10
3,026%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 3,026%upside $10 | Buy Maintained | 15 Aug 2025 |
Financial journalist opinion
Based on 5 articles about CODX published over the past 30 days
Neutral
PRNewsWire
1 week ago
Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.
SALT LAKE CITY , Aug. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will be hosting a booth at the 17th Annual Next Generation Dx Summit, held virtually and in-person at the Capital Hilton in Washington, D.C. on August 18-20, 2025.
Neutral
Seeking Alpha
1 week ago
Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2025 Earnings Conference August 14, 2025 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Brian L. Brown - CFO & Company Secretary Dwight H.
Negative
Zacks Investment Research
1 week ago
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Misses Revenue Estimates
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.25 per share a year ago.
Neutral
PRNewsWire
1 week ago
Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results
SALT LAKE CITY , Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Results: Revenue of $0.2 million, which declined from $2.7 million during Q2 2024 primarily due to timing of grant revenue recognition.
Neutral
PRNewsWire
3 weeks ago
Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast
SALT LAKE CITY , July 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2025 financial results on Thursday, August 14, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
Neutral
PRNewsWire
1 month ago
Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025
SALT LAKE CITY , July 15, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at WHX (World Health Expo) Kuala Lumpur on July 16-18, 2025, at the Malaysia International Trade and Exhibition Centre (MITEC). WHX Kuala Lumpur, formerly Asia Health/Medlab Asia, is the leading healthcare exhibition in Southeast Asia, providing networking and collaboration opportunities with industry leaders from across the globe.
Neutral
GlobeNewsWire
3 months ago
Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference
Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital (“DBC”) Inaugural Global Conference on May 14, 2025 in New York City.
Neutral
Seeking Alpha
3 months ago
Co-Diagnostics, Inc. (CODX) Q1 2025 Earnings Call Transcript
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Cath and I will be your conference operator today.
Negative
Zacks Investment Research
3 months ago
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Misses Revenue Estimates
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.31 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results
SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025.
Charts implemented using Lightweight Charts™